193 related articles for article (PubMed ID: 23696021)
1. Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.
Wu K; Huang S; Zhu M; Lu Y; Chen J; Wang Y; Lin Q; Shen W; Zhang S; Zhu J; Shi YE; Weng Z
Med Oncol; 2013; 30(3):612. PubMed ID: 23696021
[TBL] [Abstract][Full Text] [Related]
2. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
3. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
4. Stage-specific expression of breast cancer-specific gene gamma-synuclein.
Wu K; Weng Z; Tao Q; Lin G; Wu X; Qian H; Zhang Y; Ding X; Jiang Y; Shi YE
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):920-5. PubMed ID: 14504205
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.
Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A
Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236
[TBL] [Abstract][Full Text] [Related]
6. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients.
Min L; Zhang C; Ma R; Li X; Yuan H; Li Y; Chen R; Liu C; Guo J; Qu L; Shou C
BMC Cancer; 2016 Sep; 16(1):717. PubMed ID: 27595752
[TBL] [Abstract][Full Text] [Related]
8. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
[TBL] [Abstract][Full Text] [Related]
9. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer.
Wu M; Wei W; Xiao X; Guo J; Xie X; Li L; Kong Y; Lv N; Jia W; Zhang Y; Xie X
Med Oncol; 2012 Dec; 29(5):3240-9. PubMed ID: 22661383
[TBL] [Abstract][Full Text] [Related]
10. Combined phenotype of 4 markers improves prognostic value of patients with colon cancer.
Liu C; Qu L; Dong B; Xing X; Ren T; Zeng Y; Jiang B; Meng L; Wu J; Shou C
Am J Med Sci; 2012 Apr; 343(4):295-302. PubMed ID: 22261620
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
12. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
13. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.
Kim S; Jung WH; Koo JS
Tumour Biol; 2012 Oct; 33(5):1681-94. PubMed ID: 22638807
[TBL] [Abstract][Full Text] [Related]
14.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
15. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
16. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.
Zhao H; Yang M; Zhao J; Wang J; Zhang Y; Zhang Q
Med Oncol; 2013 Mar; 30(1):475. PubMed ID: 23371253
[TBL] [Abstract][Full Text] [Related]
17. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer.
Wan F; Dong L; Zhang F; Wang Y; Chen F; Ni S; Chen Y; Long J
J Int Med Res; 2013 Jun; 41(3):743-53. PubMed ID: 23696593
[TBL] [Abstract][Full Text] [Related]
19. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.
Liu C; Dong B; Lu A; Qu L; Xing X; Meng L; Wu J; Eric Shi Y; Shou C
BMC Cancer; 2010 Jul; 10():359. PubMed ID: 20604972
[TBL] [Abstract][Full Text] [Related]
20. Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Min L; Ma RL; Yuan H; Liu CY; Dong B; Zhang C; Zeng Y; Wang L; Guo JP; Qu LK; Shou CC
Asian Pac J Cancer Prev; 2015; 16(7):2819-26. PubMed ID: 25854368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
